ERBB2 and breast cancer: An investigation evaluated the common metastatic sites in different subtypes of breast cancer, including triple negative (TNBC) nonbasal, HER2 enriched, basal-like, luminal/human epidermal growth factor receptor 2 (HER2), luminal A, and luminal B. Outcomes showed that bone was the most frequent metastatic site in all breast cancer subtypes excluding basal-like tumors.